Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
Abstract Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple sclerosis (MS), but their value to predict response to treatment, and their association with patient immunological profile, need to be further explored. We studied 80 relapsing–remitting MS patients initi...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-04-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-88624-7 |
id |
doaj-8c728d8ae2de49b8accdc64e3ffacaf7 |
---|---|
record_format |
Article |
spelling |
doaj-8c728d8ae2de49b8accdc64e3ffacaf72021-05-02T11:32:46ZengNature Publishing GroupScientific Reports2045-23222021-04-011111810.1038/s41598-021-88624-7Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatmentPaulette Esperanza Walo-Delgado0Susana Sainz de la Maza1Noelia Villarrubia2Enric Monreal3Silvia Medina4Mercedes Espiño5José Ignacio Fernández-Velasco6Eulalia Rodríguez-Martín7Ernesto Roldán8Daniel Lourido9Alfonso Muriel10Jaime Masjuan-Vallejo11Lucienne Costa-Frossard12Luisa María Villar13Immunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMNeurology Department, Ramón y Cajal University Hospital, IRYCIS, REEMImmunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMNeurology Department, Ramón y Cajal University Hospital, IRYCIS, REEMImmunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMImmunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMImmunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMImmunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMImmunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMRadiology Department, Ramón y Cajal University Hospital, IRYCIS, REEMClinical Biostatistics Unit, Ramón y Cajal University Hospital, IRYCIS, University of Alcalá, CIBERESPNeurology Department, Ramón y Cajal University Hospital, IRYCIS, REEMNeurology Department, Ramón y Cajal University Hospital, IRYCIS, REEMImmunology Department, Ramón y Cajal University Hospital, IRYCIS, REEMAbstract Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple sclerosis (MS), but their value to predict response to treatment, and their association with patient immunological profile, need to be further explored. We studied 80 relapsing–remitting MS patients initiating dimethyl fumarate (DMF) treatment. sNfL levels were explored at baseline and at 3, 6 and 12 months by single molecule array. Blood lymphocyte subsets were measured at baseline and at 6 months by flow cytometry. Patients were followed a year and classified as NEDA (no evidence of disease activity) or ODA (ongoing disease activity). NEDA patients had lower sNfL levels at baseline (p = 0.0001), and after three (p = 0.004) and six (p = 0.03) months of DMF treatment. Consequently, low baseline sNfL values (≤ 12 pg/ml) increased the probability of NEDA (OR 5.8; CI 1.82–15.6; p = 0.002, after correcting by disease activity in the previous year), and associated with significant reductions of central memory CD4+ T lymphocytes, interferon-gamma+ CD8+ T lymphocytes, Natural Killer T cells, and memory B cells upon DMF treatment, being the highest differences in memory B cells (p < 0.0001). This shows that low baseline sNfL values identify MS patients with higher probability of optimal response to DMF and of a reduction in effector immune cells.https://doi.org/10.1038/s41598-021-88624-7 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paulette Esperanza Walo-Delgado Susana Sainz de la Maza Noelia Villarrubia Enric Monreal Silvia Medina Mercedes Espiño José Ignacio Fernández-Velasco Eulalia Rodríguez-Martín Ernesto Roldán Daniel Lourido Alfonso Muriel Jaime Masjuan-Vallejo Lucienne Costa-Frossard Luisa María Villar |
spellingShingle |
Paulette Esperanza Walo-Delgado Susana Sainz de la Maza Noelia Villarrubia Enric Monreal Silvia Medina Mercedes Espiño José Ignacio Fernández-Velasco Eulalia Rodríguez-Martín Ernesto Roldán Daniel Lourido Alfonso Muriel Jaime Masjuan-Vallejo Lucienne Costa-Frossard Luisa María Villar Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment Scientific Reports |
author_facet |
Paulette Esperanza Walo-Delgado Susana Sainz de la Maza Noelia Villarrubia Enric Monreal Silvia Medina Mercedes Espiño José Ignacio Fernández-Velasco Eulalia Rodríguez-Martín Ernesto Roldán Daniel Lourido Alfonso Muriel Jaime Masjuan-Vallejo Lucienne Costa-Frossard Luisa María Villar |
author_sort |
Paulette Esperanza Walo-Delgado |
title |
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment |
title_short |
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment |
title_full |
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment |
title_fullStr |
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment |
title_full_unstemmed |
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment |
title_sort |
low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-04-01 |
description |
Abstract Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple sclerosis (MS), but their value to predict response to treatment, and their association with patient immunological profile, need to be further explored. We studied 80 relapsing–remitting MS patients initiating dimethyl fumarate (DMF) treatment. sNfL levels were explored at baseline and at 3, 6 and 12 months by single molecule array. Blood lymphocyte subsets were measured at baseline and at 6 months by flow cytometry. Patients were followed a year and classified as NEDA (no evidence of disease activity) or ODA (ongoing disease activity). NEDA patients had lower sNfL levels at baseline (p = 0.0001), and after three (p = 0.004) and six (p = 0.03) months of DMF treatment. Consequently, low baseline sNfL values (≤ 12 pg/ml) increased the probability of NEDA (OR 5.8; CI 1.82–15.6; p = 0.002, after correcting by disease activity in the previous year), and associated with significant reductions of central memory CD4+ T lymphocytes, interferon-gamma+ CD8+ T lymphocytes, Natural Killer T cells, and memory B cells upon DMF treatment, being the highest differences in memory B cells (p < 0.0001). This shows that low baseline sNfL values identify MS patients with higher probability of optimal response to DMF and of a reduction in effector immune cells. |
url |
https://doi.org/10.1038/s41598-021-88624-7 |
work_keys_str_mv |
AT pauletteesperanzawalodelgado lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT susanasainzdelamaza lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT noeliavillarrubia lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT enricmonreal lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT silviamedina lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT mercedesespino lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT joseignaciofernandezvelasco lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT eulaliarodriguezmartin lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT ernestoroldan lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT daniellourido lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT alfonsomuriel lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT jaimemasjuanvallejo lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT luciennecostafrossard lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT luisamariavillar lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment |
_version_ |
1721492081020502016 |